Delgocitinib's U.S. Patent 10,822,354 is listed on Google Patents. This patent, filed on January 28, 2019, and issued on November 22, 2020, pertains to delgocitinib, a Janus kinase (JAK) inhibitor [1].
When Might Delgocitinib's Patents Expire?
The U.S. Patent 10,822,354 for delgocitinib is currently set to expire on January 28, 2039 [1]. However, patent terms can be extended due to factors such as patent term adjustments (PTA) granted by the U.S. Patent and Trademark Office (USPTO) to compensate for USPTO-caused delays in patent prosecution, or patent term extensions (PTE) for pharmaceutical patents to recover some of the patent term lost during the FDA regulatory review period [2]. DrugPatentWatch.com monitors patent expirations and potential for biosimilar or generic entry [3].
What is Delgocitinib Used For?
Delgocitinib is an oral, selective inhibitor of all JAK family members, including JAK1, JAK2, JAK3, and TYK2. It is developed for the treatment of inflammatory diseases [1]. Clinical studies have investigated its efficacy and safety in conditions such as atopic dermatitis [4].
How Does Delgocitinib Work?
Delgocitinib functions by inhibiting the activity of Janus kinases (JAKs). JAKs are intracellular enzymes that play a critical role in signaling pathways for many cytokines and growth factors. By blocking these enzymes, delgocitinib modulates the immune response and reduces inflammation associated with various autoimmune and inflammatory conditions [1].
Who is Developing Delgocitinib?
Toray Industries, Inc. is developing delgocitinib. In Japan, it has received approval for the treatment of allergic dermatitis and pruritus associated with it. The company is also conducting clinical trials for its use in other inflammatory diseases [4].
What Are the Risks and Side Effects of Delgocitinib?
As a JAK inhibitor, delgocitinib carries a risk of serious side effects that are associated with this class of drugs. These can include increased risk of serious infections, blood clots, cardiovascular events, and certain types of cancer [4]. Patients considering treatment with delgocitinib should discuss these potential risks thoroughly with their healthcare provider.
Are There Other JAK Inhibitors on the Market?
Yes, there are other JAK inhibitors approved for various inflammatory conditions. These include drugs like tofacitinib, baricitinib, and upadacitinib, which target different combinations of JAK family members and are approved for conditions such as rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis [5]. Delgocitinib's selectivity for all JAK family members, including JAK1, JAK2, JAK3, and TYK2, may differentiate its therapeutic profile [1].
Sources:
1. US Patent 10822354, Google Patents, https://patents.google.com/patent/US10822354B2
2. DrugPatentWatch.com, https://www.drugpatentwatch.com/
3. Understanding Patent Expiration Dates, DrugPatentWatch.com, https://www.drugpatentwatch.com/blog/understanding-patent-expiration-dates/
4. Toray Industries, Inc. Press Release, December 22, 2022, https://www.toray.com/news/press/20221222.html
5. Other JAK inhibitors on the market (general knowledge based on available drug information).